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Abstract
Schizophrenia neurocognitive domain profiles are predominantly based on paper-and-pencil 
batteries. This study presents the first schizophrenia domain profile based on the Computerized 
Multiphasic Interactive Neurocognitive System (CMINDS®). Neurocognitive domain z-scores 
were computed from computerized neuropsychological tests, similar to those in the Measurement 
and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery 
(MCCB), administered to 175 patients with schizophrenia and 169 demographically similar 
healthy volunteers. The schizophrenia domain profile order by effect size was Speed of Processing 
(d=−1.14), Attention/Vigilance (d=−1.04), Working Memory (d=−1.03), Verbal Learning (d=
−1.02), Visual Learning (d=−0.91), and Reasoning/Problem Solving (d=−0.67). There were no 
significant group by sex interactions, but overall women, compared to men, showed advantages on 
Attention/Vigilance, Verbal Learning, and Visual Learning compared to Reasoning/Problem 
Solving on which men showed an advantage over women. The CMINDS can readily be employed 
in the assessment of cognitive deficits in neuropsychiatric disorders; particularly in large-scale 
studies that may benefit most from electronic data capture.
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1. Introduction
Patients with schizophrenia show significant cognitive deficits (Dickinson et al., 2007; 
Heinrichs and Zakzanis, 1998; Schaefer et al., 2013). These deficits are present in first-
episode patients (Mesholam-Gately et al., 2009), non-ill relatives (Dickinson et al., 2007), 
and individuals at clinical (De Herdt et al., 2013; Giuliano et al., 2012) or genetic risk 
(Agnew-Blais and Seidman, 2013) for psychosis, suggesting that they are associated with 
disease liability and not merely a consequence of the disease or its treatment. Cognitive 
deficits among patients with schizophrenia have been associated with poorer functioning 
(Green et al., 2000; Green et al., 2004a) and hence may provide important treatment targets. 
This study assesses the schizophrenia neurocognitive domain profile based on the 
Computerized Multiphasic Interactive Neurocognitive System (CMINDS®; 
www.neurocomp.com), to determine its usability in large-scale studies of neuropsychiatric 
illness.
Neuropsychological test performance across cognitive domains (e.g., attention, working 
memory, verbal learning, etc.) is often presented as a cognitive domain profile (Saykin et al., 
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1991; Saykin et al., 1994). These profiles are created by normalizing scores using control 
means and standard deviations and grouping test scores to allow for visualization of 
putatively ‘differential’ deficits between cognitive domains. Many studies use different tests 
that have dissimilar discriminating power (Chapman and Chapman, 1973) within each of 
these cognitive domains, making comparisons of profiles across studies difficult. Meta-
analyses on neuropsychological deficits in schizophrenia handle this issue by computing 
effect sizes based on individual test scores rather than on cognitive domain scores, which 
may vary in composition across studies (Dickinson et al., 2007; Schaefer et al., 2013).
The issue of variability in the composition of test batteries is of particular relevance with 
regard to the assessment and comparison of putative pro-cognitive treatments (Green et al., 
2004b). To advance the development of such treatments, the National Institutes of Mental 
Health (NIMH) funded the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative to develop a consensus cognitive battery for use in 
schizophrenia clinical trials (Kern et al., 2008; Nuechterlein et al., 2008). The MATRICS 
initiative (1) selected tasks based on reliability, repeatability, sensitivity to site effects, 
practicality, tolerability, and relationship to functional outcome, (2) put forward the 
MATRICS Consensus Cognitive Battery (MCCB) comprised of 6 cognitive domains –
Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual 
Learning, and Reasoning/Problem Solving– and one domain of Social Cognition 
(Nuechterlein et al., 2008) and (3) has co-normed the MCCB (Kern et al., 2008). Training 
on the battery is provided via Neurcog Trials, Inc. (http://www.neurocogtrials.com). The 
MCCB has norms for English and Spanish versions in the United States, and co-norming 
and standardization of the battery are taking place in several other countries (Jedrasik-Styla 
et al., 2012; Mohn et al., 2012; Rapisarda et al., 2013; Rodriguez-Jimenez et al., 2011). In 
addition, a number of studies have now reported cognitive domain profiles based on the 
MCCB in adult patients with schizophrenia (August et al., 2011; Freedman et al., 2008; 
Javitt et al., 2012; Keefe et al., 2011; Kern et al., 2011; Marx et al., 2009; Pietrzak et al., 
2009; Rajji et al., 2013; Shamsi et al., 2011; Silverstein et al., 2010), early-onset 
schizophrenia-spectrum disorders (Holmen et al., 2009), non-ill siblings (Nam et al., 2009), 
adolescents with psychotic symptoms (Kelleher et al., 2012), and youth at clinical high-risk 
for psychosis (De Herdt et al., 2013).
In an independent effort, the NIMH sponsored the development of the Computerized 
Multiphasic Interactive Neurocognitive System (CMINDS; www.neurocomp.com). The 
CMINDS includes computerized neuropsychological tasks that are structurally- and 
functionally similar to standard paper-and-pencil neuropsychological tasks (O'Halloran et 
al., 2008) and allows for immediate electronic raw data capture and automated scoring of 
test results. Among the tasks available in the CMINDS are tests similar to those of the 
MCCB, though they differ in administration, data capture, and scoring (for review see 
(O'Halloran et al., 2008) and Table 1S). Some tasks also differ with regard to certain task 
components (Kern et al., 2009; O'Halloran et al., 2008). Unfortunately, and likely in part due 
to ongoing development of computerized neuropsychological batteries during the 
development of the MCCB, few computerized tasks, with exception of the continuous 
performance task, were incorporated into the MCCB. Though it could be argued that 
electronic data capture, which eliminates the need for manual scoring and dual data entry, 
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has at least some efficiency advantages over paper-and-pencil neuropsychological tasks. 
With increases in sample sizes in all areas of psychiatric research (Ripke et al., 2011; 
Thompson et al., 2014), efficient data capture becomes increasingly important. In addition to 
the CMINDS, there are the IntegNeuro computerized cognitive assessment battery which 
also includes some neuropsychological test similar to standard tests (Silverstein et al., 2010) 
as well as several more cognitive neuroscience oriented computerized test batteries (e.g., 
CogState (Lim et al., 2013; Pietrzak et al., 2009), STAN/JANET (Cherkil et al., 2012; Glahn 
et al., 2010), CDR (Wesnes et al., 2002), PENN CNP (Gur et al., 2001a; Gur et al., 2001b; 
Gur et al., 2012; Gur et al., 2010) and CANTAB (Fray et al., 1996; Levaux et al., 2007), all 
of which are employed in numerous research studies.
In this study, we report on the CMINDS cognitive domain profile of adult patients with 
schizophrenia (n=175) compared to demographically similar healthy volunteers (n=169) 
recruited into the Function Biomedical Informatics Research Network (FBIRN) Phase 3 
study. The cognitive domain scores were derived from computerized tasks that are similar to 
those of the paper-and-pencil MCCB. We also tested for the group and sex by domain 
interactions on performance. Keeping in mind that some proportion of the variance in each 
of the domain score distributions, for patients, is affected by a schizophrenia-related 
generalized cognitive impairment (e.g., poor attention) as well as factors such as poor 
motivation, based on the first cognitive impairment profile reported on the MCCB (Kern et 
al., 2011), we hypothesized the following ranking of deficits across the domains, from worst 
to best: Speed of Processing, Working Memory, Verbal Learning, Attention/Vigilance, 
Visual Learning, Reasoning/Problem Solving. Based on sex differences reported on the 
MCCB (Kern et al., 2008), we hypothesized a male advantage on working memory and 
problem solving and female advantage on verbal learning. Also, given recent evidence for 
confounding effects of smoking status on structural brain abnormalities (Schneider et al., 
2014) as well as cognitive deficits (Hagger-Johnson et al., 2013) and the unresolved issues 
with regard to medication effects on cognition, we examined the effects of smoking and 
antipsychotic medication dosing on cognitive performance. Finally, we examined the 
clinical correlates of global cognitive dysfunction.
2. Methods
2.1 Participants
One-hundred-and-seventy-five patients with schizophrenia (mean age±SD=39.1±11.5, 132 
males) and 169 healthy volunteers (mean age±SD=37.6±11.3, 122 males) with similar mean 
age, sex handedness, and race distributions, from 7 sites, participated in the study (see Table 
1). Patient inclusion criteria were schizophrenia diagnosis based on the Structured Clinical 
Interview for DSM-IV-TR Axis I Disorders (First et al., 2002b). All patients were clinically 
stable outpatients whose antipsychotic medications and doses had not changed within the 
last two months. Current antipsychotic medication data were available for 159 of the 166 
patients (antipsychotics: 132 atypical, 18 typical, and 9 both). Chlorpromazine equivalents 
(mean±SD=380±392) could be computed for 143 patients (www.scottwilliamwoods.com/
files/Equivtext.doc). Schizophrenia patients and healthy volunteers with a history of major 
medical illness, drug dependence in the last 5 years (except for nicotine), current substance 
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abuse disorder, or MRI contraindications, were excluded. Patients with significant tardive 
dyskinesia and healthy volunteers with a current or past history of major neurological or 
psychiatric illness (First et al., 2002a) or with a first-degree relative with an Axis-I psychotic 
disorder diagnosis were also excluded. Patient’s clinical assessments included the Positive 
and Negative Syndrome Scale (Kay et al., 1989), the Scale for the Assessment of Positive 
Symptoms (Andreasen, 1984), and the Scale for the Assessment of Negative Symptoms 
(Andreasen, 1983). Socioeconomic status (Hollingstead, 1975), handedness (Oldfield, 
1971), basic demographics, smoking history, and premorbid IQ (Uttl, 2002) were also 
assessed for all subjects. The sample includes 128 paranoid, 6 disorganized, 29 
undifferentiated, and 12 residual patients. Prior to data collection, experienced clinicians 
were jointly trained on the clinical assessment rating scales with patient interviews. The 
raters' assessments were compared with expert ratings. Additional training was provided 
when raters deviated by more than one point for each item from the expert ratings.
Written informed consent, including permission to share de-identified data between the 
centers and with the wider research community, approved by the University of California 
Irvine, Los Angeles, and San Francisco, Duke University, University of North Carolina, 
New Mexico, Iowa, and Minnesota Institutional Review Boards, was obtained from all study 
participants.
2.2 CMINDS neuropsychological test battery
The Computerized Multiphasic Interactive Neurocognitive DualDisplay System (CMINDS) 
(http://www.neurocomp.com/Solutions/Cminds/Default.aspx?page=Page3) includes 
structurally- and functionally similar, computerized administration versions of standard 
administration version tests selected by the NIMH-sponsored CATIE (Clinical 
Antipsychotic Trials of Intervention Effectiveness) and MATRICS® (Measurement and 
Treatment Research to Improve Cognition in Schizophrenia) consortia. These computerized 
tests have shown high levels of agreement with the standard tests as well as high levels of 
test-retest reliability (O'Halloran et al., 2008). The CMINDS battery was administered in 
individual testing rooms by personnel trained by neurocomp and took less than 1 hour and 
30 minutes to complete.
The CMINDS test battery employed in the FBIRN Phase 3 study included the following 
computerized tests (standard equivalent, Publisher): Finger Tapping (Finger Tapping Test, 
Reitan Neuropsychological Laboratory), the Stroop Test (Stroop Color and Word Test, 
Psychological Assessment Resources, Inc), the North American Adult Reading Test (North 
American Adult Reading Test, Public Domain), the Symbol Digit Association Test (Symbol 
Digit Modalities Test, Western Psychological Services), Trails A and B, (Trail Making Test 
Parts A and B, Reitan Neuropsychological Laboratory), the Semantic Verbal Learning Test 
(Hopkins Verbal Learning Test – Revised™, Psychological Assessment Resources, Inc.), 
the Visual Spatial Sequencing Test (WMS®-III Spatial Span, Harcourt Assessment, Inc.), 
the Letter Number Test (WAIS®-III Letter Number Sequencing, Harcourt Assessment, Inc.), 
the Maze Solving Test (WISC®-III Mazes, Harcourt Assessment, Inc.), Facial Emotion 
Discrimination (Facial Emotion Discrimination, Public Domain), Letter Fluency Test (Letter 
Fluency, Public Domain), Category Fluency Test (Category Fluency, Public Domain), the 
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Visual Figure Learning Test (Brief Visuospatial Memory Test – Revised, Psychological 
Assessment Resources, Inc.), the Continuous Performance Test – Repeated Pairs 
(Continuous Performance Test – Identical Pairs, Biobehavioral Technologies, Inc.), and the 
Card Sort Test [64 trials] (Wisconsin Card Sort Test™, Psychological Assessment 
Resources, Inc.). For detailed CMINDS task descriptions see Supplement 1. For detailed 
descriptions of standard neuropsychological tasks see reference (Lezak, 1995). At each site, 
the test battery was administered by staff trained by CMINDS personnel. Prior to test 
administration each subject performed the CMINDS Perception Response Evaluation Test 
to determine the subject’s capability of perceiving and responding to auditory and visual 
stimuli and prompts.
The CMINDS-based cognitive domains, based on comparable tests to those assessed by the 
MCCB, were as follows: (1) Speed of Processing. This domain score was based on the mean 
of (a) the log-transformed, negated (worse performance is lower) elapsed time (in seconds) 
during Trails A, (b) the number of correct in set responses in 60 seconds on trial 1 of the 
Category Fluency Test – Animals, and (c) the number of correct responses during the 
Symbol Digit Association Test z-scores; (2) Attention/Vigilance. This domain score was 
based on the d-prime across blocks A-C of the Continuous Performance Test z-scores; (3) 
Working Memory. This domain score was based on the mean of (a) the sum of the number of 
correct on the Visual Spatial Sequencing Test – Forward and Backward condition, and (b) 
the total correct on the Letter Number Span z-scores; (4) Verbal Learning. This domain 
score was based on the total number of correctly recalled target words for all three trials on 
the Semantic Verbal Learning Test z-scores; (5) Visual Learning. This domain score was 
based on the square-transformed total of the Visual Figure Learning Test z-scores, and (6) 
Reasoning/Problem Solving. This domain score was based on the square-transformed Maze 
Solving Test total score z-scores. Finally, CMINDS Composite Score was created based on 
the average across all 6 cognitive domains.
Examination of raw score distributions indicated that the Trails A variable (elapsed time) 
was notably positively skewed, while Maze Solving and Visual Figure Learning test 
variables were negatively skewed. The distributions for the positive and negatively skewed 
variables were transformed using log and square transformations, respectively. 
Subsequently, all tests scores were normalized to the control mean and SD [normalized (z) 
score = (raw score – control mean raw score) ÷ control standard deviation]. Domain 
scores that consisted of multiple test scores (e.g, speed of processing, working memory, and 
the CMINDS composite score (mean of all 6 normalized domain scores) were normalized to 
the control mean and SD a second time to account for the averaging-associated changes in 
means and standard deviations (see Table 2 for absolute test score means as well as domain 
z-scores and their standard deviations).
2.3 Statistical analyses
The group comparison of the CMINDS composite score was performed using a mixed 
effects model (Proc Mixed, SAS/STAT® version 9.2, SAS Institute, Inc., Cary, NC, USA), 
predicting the normalized composite scores with group (schizophrenia, healthy volunteer), 
sex, age, and site. Group comparisons of the domain scores were performed using a mixed 
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effects model with repeated measures (MMRM). Normalized domain scores were predicted 
with group, domain (Speed of Processing, Attention/Vigilance, Working Memory, Verbal 
Learning, Visual Learning, Reasoning/Problem Solving), and the group × domain 
interaction. Domain was modeled as a within-subject repeated measures factor and within-
subject correlations were modeled with an unstructured covariance matrix. Age, sex, and site 
were included as fixed effects covariates. Based on testing for group × sex, sex × domain, 
and group × age interactions, the sex × domain interaction was added to the model.
The significant group × domain and sex × domain interactions were followed up with 15 
contrasts comparing the magnitude of the patient versus control (or female versus male) 
differences between each of the domains. We used the Benjamini and Hochberg (1995) 
(Benjamini and Hochberg, 1995) False Discovery Rate procedure (FDR<0.05) to control for 
Type I errors. Briefly, the pairwise comparisons were sorted (ranked) from smallest to 
largest pvalue and compared with the critical p-value at each rank i, defined as P(i) = (i ÷ 
15) · 0.05. For all consecutive p-values for rank 1 to i, where the tests p-value < P(i) the 
null-hypothesis was rejected. In addition to the z-score profile, we also rank ordered the 
cognitive domain profile based on Cohen’s d effect size estimates. To place our findings in 
the context of those by others, we compared our findings to those from the most recent, and 
largest meta-analysis study of neuropsychological task performance (Schaefer et al., 2013) 
as well as published neuropsychological profiles based on the MCCB (August et al., 2011; 
Freedman et al., 2008; Javitt et al., 2012; Keefe et al., 2011; Kern et al., 2011; Marx et al., 
2009; Pietrzak et al., 2009; Rajji et al., 2013; Shamsi et al., 2011; Silverstein et al., 2010).
Possible confounding influences of smoking status on cognitive performance deficits 
(Hagger-Johnson et al., 2013) were assessed by including dummy-coded smoking status 
(current smoker, ex-smoker, never-smoker), current pack-year, or lifetime pack-year as 
covariates, respectively. We also examined the relationship between domain scores and 
antipsychotic medication dose (chlorpromazine equivalents). Estimate statements, which 
produce t-statistics, were used to determine the directionality of the relationships between 
continuous variables (e.g., age, medication dose) and CMINDS composite and domain 
scores. Finally, we examine the relationships between the CMINDS composite score and 
several clinical variables (age at onset, duration of illness, positive and negative symptoms). 
A detailed analysis of individual domain scores and clinical variables is outside the scope of 
this study and findings will be reported on in a separate manuscript.
3. Results
3.1 CMINDS composite score
Patients (marginal mean±SE=−1.62±0.10) had significantly lower CMINDS composite 
scores than controls (marginal mean±SE=0.08±0.10; t333=−12.62, p<0.0001) and the 
CMINDS composite score showed a significant negative association with age (t333=−6.66, 
p<0.0001).
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3.2 CMINDS domain profile
The MMRM analysis showed significant effects of diagnosis [F(1,330)=201.10, p<0.0001], 
age [F(1,332)=68.46, p<0.0001], domain [F(5,339)=2.42, p<0.04], and diagnosis × domain 
[F(5,339)=4.51, p=0.0005] and sex × domain interactions [F(5,339)=3.26, p<0.007], but no 
significant effects of site, sex, or the group × sex interaction on standardized 
neuropsychological domain scores.
Comparisons of group (patient vs. control) contrasts between the six cognitive domains 
(FDR-corrected) showed that patients were significantly more impaired than controls on the 
Attention/Vigilance (t338=−4.26, p<0.0001), Speed of Processing (t340=−3.63, p=0.003), 
Working Memory (t339=−3.24, p<0.0013), and Verbal Learning domains (t339=−3.07, 
p=0.0023) relative to the Reasoning/Problem Solving domain, and the Attention/Vigilance 
domain relative to the Visual Learning domain (t338=−2.8, p<0.0054; see cognitive domain 
profile in Figure 1).
Comparisons of sex (female vs. male) contrasts between the six cognitive domains (FDR-
corrected) showed that women were significantly better than men on the Attention/Vigilance 
(t341=3.22, p=0.0014), Verbal Learning (t339=3.06, p<0.0024), and Visual Learning 
(t339=2.94, p=0.0035) domains relative to Reasoning/Problem Solving domain on which 
men excelled compared to women (t338=2.11, p=0.04; see Figure 2).
3.3 Ranking of cognitive domain deficits based on their effect sizes
Based on Cohen’s d effect sizes, the rank ordering of cognitive domain deficits for patients 
with schizophrenia compared to healthy controls was Speed of Processing (d=−1.14), 
Attention / Vigilance (d=−1.04), Working Memory (d=−1.03), Verbal Learning (d=−1.02), 
Visual Learning (d=−0.91), and Reasoning / Problem Solving (d=−0.67). Patients were 
significantly more impaired than controls on the Attention/Vigilance, Speed of Processing, 
Working Memory, and Verbal Learning domains relative to the Reasoning/Problem Solving 
domain, and the Attention/Vigilance domain relative to the Visual Learning domain (see 
section 3.2 and Figure 1).”
3.4 Smoking and medication
There were no significant effects of smoking status, current or lifetime pack-year on the 
CMINDS composite score or on any of the individual cognitive domain scores. Among the 
cognitive domain scores (including the CMINDS composite score), only Reasoning/Problem 
Solving was significantly negatively associated with chlorpromazine dose equivalents (t143=
−0.21, p=0.01, uncorrected).
3.5 Clinical correlates
CMINDS composite scores showed significant negative correlations with PANSS Negative 
(r=−0.23, p<0.003), PANSS Positive (r=−0.23, p<0.003), PANSS Disorganized (item P2; r=
−0.25, p<0.001), and PANSS General (r=−0.23, p<0.003) symptom severity ratings as well 
as duration of illness (r=−0.30, p<0.0001) but not age at onset (r=−0.15, p>0.05). The 
symptom correlations remained significant even after partial correlations, controlling for 
duration of illness, age, or age at onset, were computed. The correlation between the 
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CMINDS composite score and duration of illness was not significant after co-varying for the 
effect of age (partial r=0.06, p=0.42).
4. Discussion
This is the first study to report the CMINDS schizophrenia cognitive domain profile. The 
ranking of CMINDS cognitive domain deficits in patients with schizophrenia based on 
effect sizes was Speed of Processing (d=−1.14), Attention/Vigilance (d=−1.04), Working 
Memory (d=−1.03), Verbal Learning (d=−1.02), Visual Learning (d=−0.91), and Reasoning/
Problem Solving (d=−0.67). The cognitive domain profile based on z-scores was largely 
similar with the exception that the z-score for Attention/Vigilance was non-significantly 
lower than that of Speed of Processing. Decomposition of the significant group by domain 
interaction showed that patients were significantly more impaired than controls on the 
Attention/Vigilance, Speed of Processing, Working Memory, and Verbal Learning domains 
relative to the Reasoning/Problem Solving domain, and the Attention/Vigilance domain 
relative to the Visual Learning domain. Decomposition of the significant group by sex 
interaction, showed that women were significantly better than men on the Attention/
Vigilance, Verbal Learning, and Visual Learning, domains relative to Reasoning/Problem 
Solving domain, and vice versa. Patient’s cognitive deficits were not significantly associated 
with smoking status, or current/lifetime pack years. Among the cognitive domains, only 
reasoning/problem solving showed a significant negative association with medication dose 
in chlorpromazine equivalents. More severe cognitive impairment was associated with 
higher symptom severity.
The finding of the largest deficit in speed of processing and the smallest in reasoning/
problem solving in patients with schizophrenia, compared to healthy volunteers, is 
consistent with findings from meta-analyses (Dickinson et al., 2007; Schaefer et al., 2013) as 
well as many, though not all (Nam et al., 2009; Shamsi et al., 2011), studies that used the 
MCCB (Freedman et al., 2008; Javitt et al., 2012; Keefe et al., 2011; Kern et al., 2011; 
Silverstein et al., 2010). Domain profiles are traditionally based on z- or T-scores, thought it 
could be argued that domain profiles based on effect sizes rather than z-scores are more 
appropriate give that effect sizes also take into account variance in the patient sample, while 
z- and T-score profiles do not. The effect size for speed of processing based on the CMINDS 
is smaller than that observed in the MCCB battery, which is most likely due to task 
differences in the Digit Symbol Coding task, which in the CMINDS does not require hand-
eye coordination and graphomotor speed (Kern et al., 2009) because subjects provide their 
answers verbally instead of in writing (see (Bachman et al., 2010) for additional analyses 
about the contributions of cognitive processes to digit symbol coding task performance). 
Importantly, despite the considerable efforts in the formation of the MCCB as well as in the 
creation of the CMINDS, the group by domain interaction must be interpreted with caution 
given the inherent difficulties in establishing tests of comparable discriminability between 
groups across domains (Chapman and Chapman, 1973). Some attempts to create tasks of 
comparable discriminability have been put forward in the cognitive sciences (e.g. (Calev, 
1984)) but to our knowledge such endeavors have not been undertaken for 
neuropsychological tests.
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We did not find significant group by sex interaction effects on cognitive domain scores and 
the presence of differential sex effects on cognition in schizophrenia remains controversial 
(Krysta et al., 2013). We did find that women performed better than men on Attention/
Vigilance, Verbal Learning, and Visual Learning compared to Reasoning/Problem solving 
on which men performed better than women. Better performance among women than men 
on verbal learning and worse performance on reasoning problem solving are consistent with 
findings from the MCCB battery (Kern et al., 2008; Mohn et al., 2012; Rodriguez-Jimenez 
et al., 2011), though findings for attention/vigilance are mixed, with two studies showing 
better performance in men than women (Mohn et al., 2012; Rodriguez-Jimenez et al., 2011) 
and one showing no difference between the sexes (Kern et al., 2008). Small sex differences 
in performance on some neuropsychological tasks, including male advantage for some 
spatial tasks (e.g., block design) and female advantage for short term memory, verbal 
fluency, and verbal memory (Gur and Gur, 2002) are well-documented, though it has long 
been recognized that a simple spatial versus verbal domain accounting of sex differences is 
insufficient (Kolb and Whishaw, 1990). The neural underpinnings of sex differences in 
cognitive performance are being investigated using state-of-the art neuroimaging tools 
(Satterthwaite et al., 2014). A recent resting state functional magnetic resonance imaging 
study found that men showed stronger between-module connectivity while women showed 
stronger within-module connectivity and that subjects’ pattern of connectivity, i.e., the 
relative strength of between- versus within-module connectivity, was associated with a more 
masculine or feminine cognition profile, even when examined within the sexes 
(Satterthwaite et al., 2014).
With regard to possible confounding effects of smoking, consistent with some (Van Haren et 
al., 2013) but not all structural imaging studies (Schneider et al., 2014), we found no 
confounding effect of smoking status, current pack-years, of lifetime pack-years on 
neurocognitive domain deficits. With regard to confounding effects of antipsychotic 
medications, we only found that medication dose (in chlorpromazine equivalents) predicted 
worse reasoning/problem solving among patients. This effect did not survive a multiple 
comparison corrected threshold and must therefore be treated with caution until replicated 
by other studies. We found significant correlations between the CMINDS composite score 
and negative, positive, and general symptom severity. These findings suggest that general 
cognitive impairment as measured by the CMINDS composite score is associated with 
severity of illness. The cognitive domains contributing to these significant correlations 
require detailed further analyses that are outside the scope of the current manuscript. While 
we observed a significant correlation between the CMINDS composite score and duration of 
illness, this correlation did not remain significant after co-varying for age. Given that we 
also did not observe a significant group by age interaction effect on cognitive performance, 
we cannot conclude that cognitive performance among patients decreases with duration of 
illness or is differentially influenced by age in patients with schizophrenia compared with 
controls.
Silverstein and colleagues (2010) have reported an increased interest in computerized 
neuropsychological batteries for use in clinical trails in their report on the comparison 
between the IntegNeuro computerized neuropsychological test battery and the MCCB 
(Silverstein et al., 2010). The main goal of the MATRICS initiative was to achieve a 
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standardized battery to test pro-cognitive agents and clearly the further development of 
computerized neurocognitive battery efforts should not get in the way of this important 
objective. Even so, given the higher efficiency of data collection, e.g., no need for manual 
scoring and dual data entry, the field as a whole may want to consider the use of 
computerized batteries. With the ever increasing sample sizes of studies aimed at making 
discoveries on disease etiology (Ripke et al., 2011; Thompson et al., 2014) and treatment 
(Keefe et al., 2011; Rajji et al., 2013), we believe that computerized batteries will have and 
important role to play in future cognitive assessments in neuropsychiatric disorders.
Strengths of the study are the large sample of 175 patients with schizophrenia and 169 
demographically similar controls, and the use of a mature computerized test battery, the 
CMINDS, with tasks similar to those in the MCCB. Several weaknesses must also be noted. 
First, the study only included the CMINDS such that a direct comparison to the MCCB 
profile was not possible. A second weakness is that the CMINDS does not include tests 
directly comparable to the one used to measure the domain of social cognition in the MCCB. 
A third weakness is that the computerized digit symbol coding task differs from the paper 
and pencil task in that the former does not require hand-eye coordination/graphomotor 
integration –though, this alternative version could have advantages when assessing patients 
with reduced motor abilities, such as traumatic brain injury or stroke patients and may also 
allow for a better assessment of mental speed of processing abilities between conditions 
where one is confounded by motor slowing and the other is not. Finally, our study did not 
assess University of California Performance-Based Skills Assessment-2 (UPSA-2), which 
links cognitive performance to everyday functioning in schizophrenia and has been 
associated with the MCCB composite score (Keefe et al., 2011; Shi et al., 2013).
Strengths of the CMINDS include its ease of administration and electronic data capture and 
scoring, which make it very amenable to large-scale studies. In addition, the CMINDS tests 
are highly reliable (O'Halloran et al., 2008; O'Halloran et al., 2011) and its test scores are 
highly correlated with the comparable paper and pencil MCCB (O'Halloran et al., 2008) as 
well as Alzheimer's Disease Assessment Scale: Cognitive Subscale (ADASCog) test scores 
(O’Halloran et al. 2011). The CMINDS also includes parallel task versions with different 
stimuli to counter practice effects based on repeat administration, though to our knowledge 
no reports using these parallel version have been published. Therefore, the susceptibility of 
CMINDS test to training effects remains to be fully determined. Finally, the CMINDS is 
compliant with computerized clinical data collection standards, including 21 CFR Part 11, 
HIPAA, etc. (O'Halloran et al., 2008). A drawback is that, currently, the CMINDS does not 
yet provide English and Spanish norms, which may make it a less attractive choice for 
studies that do not include a comparison group. Advantages of the MCCB are (1) the 
availability of Spanish and English norms in the United States (US); moreover, norms are 
available or at various stages of development in numerous other countries including Spain, 
China, Russia, India, Central and South America, and Norway (Jedrasik-Styla et al., 2012; 
Kern et al., 2008; Mohn et al., 2012; Rapisarda et al., 2013; Rodriguez-Jimenez et al., 2011), 
and (2) its FDA-approval for use in testing pro-cognitive treatments. These features, 
currently, may make the MCCB the most attractive choice for clinical trails that do not 
include a control group.
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In sum, we have reported on the CMINDS neuropsychological profile, which includes 6 of 
the 7 cognitive domains included in the MCCB. We conclude that the CMINDS 
schizophrenia cognitive domain profile show the largest impairment in speed of processing, 
followed by attention/vigilance, working memory, verbal learning, visual learning, and 
reasoning/problem solving and that the battery can readily be employed in the assessment of 
cognitive deficits in neuropsychiatric disorders such as schizophrenia and may be 
particularly useful for large-scale case-control studies in which efficient electronic data 
capture is most beneficial.
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Refer to Web version on PubMed Central for supplementary material.
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• This study presents the first CMINDS® battery schizophrenia cognitive domain 
profile
• The schizophrenia profile shows the strongest effect size for speed of processing
• Women perform better than men on attention, speed of processing, and verbal 
learning
• Men perform better than women on reasoning
• Computerized neuropsychological batteries can be used in neuropsychiatric 
studies
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CMINDS Schizophrenia Cognitive Domain Profile
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CMINDS Sex Differences Cognitive Domain Profile
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Mean Age (SD) 39.1 (11.5) 37.6 (11.3) t342=1.24 0.22
Subject Educationb (SD) 3.4 (1.0) 2.2 (0.9) t342=11.46 <0.0001
Parental Educationb (SD) 2.3 (1.9) 2.2 (1.5) t342=0.85 0.40
NAART 29.6 (12.6) 39.9 (11.3) t339 = −7.99 <0.0001
Age at Onset 21.7 (7.5)
Duration of Illness 17.5 (11.4)
PANSS positive 15.4 (5.0)
PANSS negative 14.6 (5.5)
PANSS general 28.5 (7.5)
PANSS composite 0.8 (6.4)
Sex (Male/Female) 132/43 122/47 χ21=0.46 0.49
Handednessa (bilateral/left/right) 3/13/159 2/8/159 FET 0.60
Race FET 0.10
   American Indian or Alaskan Native 4 3
   Asian 21 14
   Black or African American 33 18
   Native Hawaiian or Pacific Islander 3 2
   White 114 132
Smoking Status Χ22=68.5 <0.0001
   Current Smoker 81 (46%) 14 (8%)
   Ex-Smoker 32 (18%) 30 (18%)
   Never-Smoker 62 (36%) 125 (74%)
Smoking - Current Pack-years 6.7 (13.0) 1.9 (7.2) t341=4.2 < 0.0001
Smoking -Lifetime Pack-years 10.7 (16.4) 2.3 (8.7) t340=5.9 < 0.0001
FET=Fisher’s Exact Test
a
based on Edinburgh Handedness Inventory (Oldfield, 1971)
b
based on the Hollingstead Socioeconomic Status Scale (Hollingstead, 1975)
NAART = North American Adult Reading Test (Uttl, 2002)
PANSS = Positive and Negative Syndrome Scale (Kay et al., 1989)
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Table 2
Absolute CMINDS Test Scores and Domain Z-scores by Diagnosis and Sex










Attention/Vigilance −1.42 (1.43) 0 (1) −0.81 (1.4) −0.43 (1.4)
   Continuous Performance Test (CPT) 2.3 (0.9) 3.2 (0.6) 2.7 (0.9) 3 (0.9)
Speed of Processing −1.29 (1.09) 0 (1) −0.69 (1.2) −0.56 (1.23)
   Trails A (TA) 36.1 (13.5) 26.3 (9.1) 31.6 (12.3) 30.4 (13.2)
   Category Fluency Test (CFT) 20.1 (6.4) 24.7 (6.4) 22.2 (7) 22.7 (6.2)
   Symbol Digit Association Test (SDAT) 39.3 (11.6) 53 (11.2) 45.6 (13.4) 47.2 (13.1)
Verbal Learning −1.28 (1.2) 0 (1) −0.73 (1.3) −0.44 (1.27)
   Semantic Verbal Learning Test (SVLT) 22.8 (5.1) 28.3 (4.3) 25.2 (5.4) 26.4 (5.4)
Working Memory −1.21 (1.15) 0 (1) −0.61 (1.2) −0.61 (1.21)
   Visual Spatial Sequencing Test (VSST) 13.9 (4.2) 17.2 (3.2) 15.6 (4.1) 15.2 (4)
   Letter Number Test (LNT) 8.8 (2.7) 11.7 (3) 10.1 (3.3) 10.6 (3.1)
Visual Learning −1.06 (1.14) 0 (1) −0.61 (1.2) −0.36 (1.12)
   Visual Figure Learning Test (VFLT) 21.6 (7.7) 28.2 (5.6) 24.4 (7.7) 26 (6.9)
Reasoning/Problem Solving −0.81 (1.24) 0 (1) −0.36 (1.2) −0.57 (1.15)
   Maze Solving Test (MST) 22.8 (4.2) 25.3 (3.2) 24.2 (4) 23.6 (3.6)
CMINDS Composite Score −1.66 (1.34) 0 (1) −0.91 (1.4) −0.66 (1.44)
Domain Z-scores are listed in bold. Score definitions: CPT: mean d-prime across blocks A to C; TA: elapsed time in seconds; CFT: number of in 
set responses in 60 seconds on trial 1; SDAT: number of correct responses; SVLT: total number of correctly recalled target words for all three 
trials; VSST: sum of number correct on forward and backward condition; LNT: total number correct; VFLT: total number correct; MST: total 
number correct.
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